July 14, 2022
1 min watch
Save
VIDEO: ‘Revolutionary’ treatment findings in early-stage lung cancer presented at ASCO
Ravi Salgia, MD, PhD, spoke with Healio about a study assessing the safety and efficacy of three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy compared with two cycles in patients with early-stage lung cancer.
The findings were presented at ASCO Annual Meeting.
The study was “revolutionary for us to think about,” according to Salgia, medical oncologist, professor and Arthur & Rosalie Kaplan Chair of the medical oncology and therapeutics research department at City of Hope.
References:
- Qiu F, et al. Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Salgia reports no relevant financial disclosures.